[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100585742":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":37,"responsibleParty":128,"collaborators":26,"id":130,"slug":131,"hasResults":132,"nctId":133,"briefTitle":134,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":132,"sex":137,"minAge":138,"maxAge":139,"enrollmentInfo":140,"targetDuration":26,"studyType":143,"phases":144,"briefSummary":146,"conditions":147,"keywords":149,"overallStatus":117,"whyStopped":26,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":162},{"fullName":5,"class":6},"Nantes University Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Cognitive remediation program","EXPERIMENTAL","The cognitive remediation program under study (experimental treatment) consists of cognitive exercises performed on computers, in 30-45 minute sessions. The cognitive exercises target the deficits commonly observed in ADHD, a fortiori when it is associated with addictive disorders (working memory, inhibitory control, cognitive flexibility, attention, planning). The proposed program will be based on a software solution for cognitive rehabilitation, developed and validated for the treatment of attention and memory disorders and neurodegenerative, neurotraumatic and neuropsychiatric pathologies (PRESCO® software, marketed by HappyNeuron).",[13],"Behavioral: Cognitive remediation program, with the PRESCO® software",{"label":15,"type":16,"description":17,"interventionNames":18},"Control program","ACTIVE_COMPARATOR","For the control program (comparator), we will use a software solution from the same company, but dedicated to stimulating and training auditory functions (AUDITICO® software). The advantage of this solution is that, like PRESCO®, it offers training exercises that are not aimed at re-educating cognitive functions. These include, for example, sound identification and discrimination activities. This tool can also be used by anyone, and is accessible for follow-up by the practitioner. It also offers levels of increasing difficulty, making it stimulating for users.",[19],"Behavioral: Control program, with the AUDITICO® software",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"BEHAVIORAL","Cognitive remediation program, with the PRESCO® software","The program runs for 16 weeks, with two sessions per week, one with a neuropsychologist. In the first 4 weeks, the patient will have weekly sessions at the center and complete the other session at home using the app provided for the study. For the next 8 weeks, sessions with the neuropsychologist will be every other week, with the other session at home. The neuropsychologist will track progress through the software history and follow up by phone if needed.\n\nThe proposed program will be based on a software solution for cognitive rehabilitation, developed and validated for the treatment of attention and memory disorders and neurodegenerative, neurotraumatic and neuropsychiatric pathologies (PRESCO® software, marketed by HappyNeuron).",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Control program, with the AUDITICO® software","Control program, with the same functional characteristics but without the targeted cognitive functions.\n\nFor the control program (comparator), we will use a software solution from the same company, but dedicated to stimulating and training auditory functions (AUDITICO® software). The advantage of this solution is that, like PRESCO®, it offers training exercises that are not aimed at re-educating cognitive functions. These include, for example, sound identification and discrimination activities. This tool can also be used by anyone, and is accessible for follow-up by the practitioner. It also offers levels of increasing difficulty, making it stimulating for users.",[15],[32],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Clémence Dr Cabelguen, MD-Phd","CONTACT","33240846116","clemence.cabelguen@chu-nantes.fr",[38,57,71,86,100,115],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"CHRU Brest","NOT_YET_RECRUITING","Brest","Brittany Region","29609","France","FR",{"type":47,"coordinates":48},"Point",[49,50],-4.48628,48.39029,{"lat":50,"lon":49},[53],{"name":54,"role":34,"phone":55,"phoneExt":26,"email":56},"Morgane Dr GUILLOU-LANDREAT, MD-PhD","33298342348","morgane.guillou@chu-brest.fr",{"facility":58,"status":40,"city":59,"state":42,"zip":60,"country":44,"countryCode":45,"cosmosGeoPoint":61,"geoPoint":65,"contacts":66},"EPSM du Finistère Sud","Quimper","29000",{"type":47,"coordinates":62},[63,64],-4.09795,47.99597,{"lat":64,"lon":63},[67],{"name":68,"role":34,"phone":69,"phoneExt":26,"email":70},"Stéphane Dr BILLARD, MD-PhD","33298986600","sbillard@epsm-quimper.fr",{"facility":72,"status":40,"city":73,"state":74,"zip":75,"country":44,"countryCode":45,"cosmosGeoPoint":76,"geoPoint":80,"contacts":81},"EPSM Georges Daumézon (Fleury-les-Aubrais, Loiret)","Fleury-les-Aubrais","Centre-Val de Loire","45400",{"type":47,"coordinates":77},[78,79],1.91811,47.93328,{"lat":79,"lon":78},[82],{"name":83,"role":34,"phone":84,"phoneExt":26,"email":85},"Raphaël Dr SERREAU, MD-Phd","33251829319","raphael.serreau@epsm-loiret.fr",{"facility":87,"status":40,"city":88,"state":74,"zip":89,"country":44,"countryCode":45,"cosmosGeoPoint":90,"geoPoint":94,"contacts":95},"CHRU de Tours","Tours","37000",{"type":47,"coordinates":91},[92,93],0.70398,47.39484,{"lat":93,"lon":92},[96],{"name":97,"role":34,"phone":98,"phoneExt":26,"email":99},"Paul Dr BRUNAULT, MD-PhD","33234379631","paul.brunault@univ-tours.fr",{"facility":101,"status":40,"city":102,"state":103,"zip":104,"country":44,"countryCode":45,"cosmosGeoPoint":105,"geoPoint":109,"contacts":110},"CH Georges Daumézon - Bouguenais","Bouguenais","Loire-Atlantique","44342",{"type":47,"coordinates":106},[107,108],-1.62468,47.17941,{"lat":108,"lon":107},[111],{"name":112,"role":34,"phone":113,"phoneExt":26,"email":114},"Jennyfer Dr CHOLET, MD-PhD","33251829300","jennyfer.Cholet@ch-gdaumezon.fr",{"facility":116,"status":117,"city":118,"state":26,"zip":26,"country":44,"countryCode":45,"cosmosGeoPoint":119,"geoPoint":123,"contacts":124},"CHU Nantes","RECRUITING","Nantes",{"type":47,"coordinates":120},[121,122],-1.55336,47.21725,{"lat":122,"lon":121},[125],{"name":126,"role":34,"phone":127,"phoneExt":26,"email":36},"Clémence CABELGUEN","02 40 84 61 16",{"type":129,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100585742","methylphenidate-in-adhd---addictions-comorbidity-value-of-adding-a-cognitive-remediation-program-to-improve-short--and-medium-term-therapeutic-response-100585742",false,"NCT06906328","MEthylphenidate in ADHD - Addiction(s) Comorbidity: Value of Adding a Cognitive Remediation Program to Improve Short- and Medium-term Therapeutic Response","META","Inclusion Criteria:\n\n* Age over 18;\n* Diagnosis of ADHD confirmed by DIVA-5 interview following a specialized ADHD-addiction(s) consultation;\n* Indication for MPH treatment according to European recommendations (J. J. S. Kooij et al., 2019) and absence of contraindications (particularly cardiological);\n* Presence of at least one comorbid addictive disorder (SUD and\u002For BA);\n* Having given their consent to take part in the study;\n* Being affiliated to the French social security system or benefiting from such a system.\n\nExclusion Criteria:\n\n* Presence of disorders of the higher functions or difficulties in reading or writing the French language making it impossible to collect data;\n* Pregnant or breast-feeding woman;\n* Person deprived of liberty;\n* Person under compulsory psychiatric care;\n* Participation in another interventional research protocol involving another psychotherapeutic or pharmacological intervention that may have an impact on clinical outcome;\n* Guardianship or safeguard of justice.\n* Patients who consumned psychoactive substances within 12 hours prior to their visit.","ALL","18 Years","99 Years",{"count":141,"type":142},248,"ESTIMATED","INTERVENTIONAL",[145],"NA","MEthylphenidate in ADHD - Addiction(s) comorbidity: benefit of adding a cognitive remediation program to improve short- and medium-term therapeutic response",[148],"ADHD-add",[150,151,152],"Methylphenidate","Cognitive remediation","Functional improvement","2026-02-16",{"date":155,"type":156},"2026-02-19","ACTUAL",{"date":158,"type":156},"2025-12-11",{"date":160,"type":142},"2029-12-11",{"name":5,"class":6},6]